Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome Sequencing of Neo-2/15 stimulated CAR-NK cells

ABSTRACT: Transcriptome Sequencing of Neo-2/15 stimulated CAR-NK cells

PROVIDER: PRJNA1018869 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26108971_1.fastq.gz	Fastqsanger.gz
	SRR26108971_2.fastq.gz	Fastqsanger.gz
	SRR26108972_1.fastq.gz	Fastqsanger.gz
	SRR26108972_2.fastq.gz	Fastqsanger.gz
	SRR26108973_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Transcriptome Sequencing of Neo-2/15 stimulated CAR-NK cells

Project description:We performed transcriptome sequencing on Neo-2/15 stimulated CAR NK cells,to shed light on the function and phenotype changes of CAR-NK cells stimulated by IL-2 and Neo-2/15.

2023-12-31 | GSE243530 | GEO

Motif-enrichment analysis identified binding sites for XBP1s in Neo-2/15 stimulated BBζ NK cells following co-cultured with AsPC-1 cells

Project description:Motif-enrichment analysis identified binding sites for XBP1s in Neo-2/15 stimulated BBζ NK cells following co-cultured with AsPC-1 cells, as determined using CUT&TAG-seq, were mainly at the gene encoding nuclear respiratory factor 1 (NRF1)

2023-12-31 | GSE243385 | GEO

Human Immune Exhaustion Gene Expression Profile in C7R-CAR and CAR NK cells

Project description:The purpose of this experiment was two-fold. The first was to examine how the gene expression profile changes over time in C7R-CAR NK cells. C7R is a constitutively active IL-7 receptor that provides persistent activation of STAT5. The second was to examine the differential gene expression in C7R CAR NK cells or CAR NK treated with exogenous IL-15 (exIL15) after 2 weeks of stimulation.

2024-09-30 | GSE277499 | GEO

NK cells engineered with a IL-15/IL-15Rα complex and CD19-targeted CAR show in vitro expansion and tumor regression in a murine xenograft model of B-cell leukemia in vivo

Project description:Natural killer (NK) cells are an attractive therapeutic approach as alternative chimeric antigen receptor (CAR) carriers and unlike T cells, offer their use in allogeneic settings. The translation of NK cells into the clinic is still hampered by the inability of CAR-NK cells to expand in vitro and in vivo. Adoptive transfer of CAR-NK cells holds the promise of therapeutic benefit with a lower rate of adverse events due to the absence of GvHD and cytokine release syndrome. However, adoptive transfer of CAR-NK cells has not yet achieved breakthrough clinical results, and further improvement of CAR-NK cells is necessary. Here, we demonstrated that a fourth-generation CD19-targeted CAR (CAR.19) co-expressing IL-15 linked to its receptor IL-15/IL-15Rα (CAR.19-IL-15/IL-15Rα) significantly enhanced NK-92 cell proliferation, proinflammatory cytokine secretion, and cytotoxic activity against B-cell cancer cell lines in vitro and in a xenograft mouse model. Surprisingly, CAR construct comprising the IL-15/IL-15Rα was superior to CAR co-expressing the soluble form of IL-15 in terms of sustained proliferation, viability, but importantly also in their ability to control CD19+ B-cell lymphoma in a murine xenograft model. Together with the results of the systematic analysis of the transcriptome of activated NK-92 CAR variants, this supports the notion that IL-15/IL-15Rα comprising fourth-generation CARs may overcome the limitations of NK cell-based targeted tumor therapies in vivo by providing the necessary growth and activation signals

2023-08-29 | GSE234733 | GEO

Phosphoproteomics of Natural Killer (NK) Cells Stimulated with Fibrin and IL-15

Project description:Phosphoproteomic analysis of fibrin or IL-15 treated NK cells with timsTOF HT

2024-06-26 | PXD049692 | Pride

IL-15 Complex-Stimulated NK cells Protect Mice from Cerebral Malaria

Project description:IL-15 Complex-Stimulated NK cells Protect Mice from Cerebral Malaria

| PRJNA431432 | ENA

IL-15 Complex-Stimulated NK cells Protect Mice from Cerebral Malaria

Project description:We report a comparison of purified mouse NK cells from mice treated in vivo with either IL-2 cytokine complexes or IL-15 cytokine complexes. We isolated RNA and performed HiSeq 2500 analysis on paired end reads of 125 base pairs in triplicate. We find relatively few significant gene expression changes between the groups, but discovered that IL-10 was induced with IL-15 cytokine complex treatment. We show that NK produced IL-10 rescues mice from lethal cerebral malaria.

2019-01-24 | GSE109586 | GEO

Motif-enrichment analysis identified binding sites for XBP1s in Neo-2/15 stimulated BBζ NK cells following co-cultured with AsPC-1 cells

Project description:Motif-enrichment analysis identified binding sites for XBP1s in Neo-2/15 stimulated BBζ NK cells following co-cultured with AsPC-1 cells

| PRJNA1018231 | ENA

CITE-seq of CAR-NK cells

Project description:Primary chimeric antigen receptor (CAR) natural killer (NK) cells show strong cytotoxic efficacy against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is often impaired by tumor-mediated immune cell inactivation. Here, we report a novel strategy to overcome NK cell inhibition caused by the immune checkpoint NKG2A, which interacts with HLA-E expressed on AML blasts. We generated AML-specific CD33-directed CAR (CAR33)-KLRC1ko-NK cells with CRISPR/Cas9-based gene editing of the NKG2A-encoding KLRC1 gene. Single-cell multi-omic analyses revealed a higher proportion of activated cells in CAR33-NK- and CAR33-KLRC1ko-NK pools, which were preserved following AML-cell contact. This activated state of the CAR33-KLRC1ko-NK cells has been translated into improved antileukemic activity in vitro and in vivo against AML cell lines and primary blasts. This dual modification of primary NK cells has the potential to bypass the suppressive effect not only of AML but also in a broad range of other cancer identities.

2024-07-16 | GSE221552 | GEO

CAR-NK cells derived from cord blood predominantly originated from CD56-CD7+CD34-HLA-DR- lineage markers- NK progenitor cells

Project description:Cord blood (CB)-derived chimeric antigen receptor (CAR)-natural killer (NK) cells targeting CD19 has been shown to be effective against B cell malignancies. While human CD56+ NK cells can be expanded in vitro, it is also known that NK cells can be differentiated from hematopoietic progenitor cells. It is still unclear whether CAR-NK cells are originated from mature NK cells or NK progenitor cells in CB. Here we found that CAR-NK cells are predominantly derived from the CD56- NK progenitor cells. We first found that substantial numbers of CD19 CAR-NK cells were produced from the CD56- CB mononuclear cells after in vitro culture for two weeks. Single cell RNAseq analysis of CD56-CD3-CD14-CD19- CB mononuclear cells revealed that those cells were subdivided into three subpopulations based on the expression of CD34 and HLA-DR. NK cells were predominantly produced from the CD34-HLA-DR- cells. In addition, in the CD34-HLA-DR- cells, only CD7+ cells could differentiate into NK cells. These results indicate that CD56-CD7+CD34- HLA-DR-lineage marker (Lin)- cells are the major origin of human CB-derived CAR-NK cells, indicating that we need to develop methods to enhance the quality and quantity of NK cells produced from these NK cell progenitor cells.

2024-12-18 | GSE253575 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data